Biogen Idec (NASDAQ: BIIB) announced interim results from the Phase Ib study of BIIB037 in Alzheimer’s disease at the Deutsche Bank BioFEST conference on December 2, 2014. The drug showed a statistically significant improvement in patient’s cognition and a dose- and time-dependent reduction in amyloid levels.
The company said “we’re actually planning very aggressively to start the Phase III program.” Biogen Idec’s stock rose 6.43% which means the market capital increased nearly $ 5 billion on Tuesday.
BIIB037 is a novel fully human anti-Aβ monoclonal antibody that binds strongly to fibrillar Aβ in plaques but less well to vascular amyloid. Previously, Eli Lilly’s solanezumab and Pfizer/J&J’s bapineuzumab, have demonstrated great potential in early trials only to fail in Phase III. However, BIIB037 has its own story.
Neurimmune identified the antibody using the Reverse Translational Medicine platform which focuses on individuals who share certain unusual capability to successfully fight a severe disease. BIIB037 was originally derived from healthy, aged donors whose immune systems had successfully resisted Alzheimer’s disease. Biogen Idec in-licensed BIIB037 from Neurimmune in 2007, with an aggregate of $ 380 million payments.
The full Phase Ib data will be presented at an upcoming medical meeting. Wait and see.